Precision AQ

Overview

Precision AQ is the market-access agency arm of Precision Medicine Group (PMG), operating after the May 2024 rebrand from Precision Value & Health (legacy: Precision for Value). The brand unified nine formerly separate agencies under one identity; “AQ” stands for Access Quotient. Buyers searching Precision Value & Health, Precision for Value, or PVH should evaluate Precision AQ as the active entity.

Precision AQ is an agency network with proprietary payer-data assets, not a pure strategy consultancy or a hub operator. The buyer thesis is the combination: in-house panel of ex-payer executives (Access Experience Team) plus payer/claims data tools (Payer Master, AccessGenius) plus an omnichannel HCP platform (Navigator365).

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Precision AQ is evaluated as market-access agency arm of Precision Medicine Group (PMG), operating after the May 2024 rebrand from Precision Value & Health (legacy: Precision for Value).

Capability	Buyer should compare	Precision AQ readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core. Largest market-access-specialized agency network; Payer Master integrates 100% of syndicated market-access data.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core. PRECISIONadvisors carries global pricing and market-access strategy.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Core. HEOR, evidence synthesis, and dossier work sit inside the agency network; Emma Hawe joined as SVP Evidence Synthesis in Feb 2026.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Core. Access Experience Team (25+ ex-payer/PBM executives) provides operator-grade payer input and panel access.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core. Payer Master and AET cover the policy/IRA/Medicaid lane; AccessGenius surfaces formulary and claims signal.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Core. Navigator365 + AccessGenius (embedded in Veeva and IQVIA OCE) push access tools directly into account-team workflows.

Buyer Fit

• Best shortlist motion: Launch teams that want payer strategy, evidence synthesis, payer data tools, and HCP/account-team activation under one network.
• Best-fit buyers: Specialty, rare-disease, oncology, and cell/gene launches where ex-payer panel access and embedded formulary/claims signal matter.
• Less ideal fit: Buyers wanting a single boutique with one named senior operator; buyers who prefer best-of-breed independent shops over an agency-network model.
• Commercial fit: Custom/RFP with agency retainer plus project SOWs; Payer Master, AccessGenius, and Navigator365 access typically scoped per engagement.
• Validate before award: Which legacy sub-agency (PRECISIONadvisors, PRECISIONxtract, others) is doing each workstream, and how the network governs cross-agency deliverables.

Differentiators

• Access Experience Team (25+ ex-payer/PBM executives): Operator panel few competitors can match for primary payer input.
• Payer Master: Integrates 100% of syndicated and channel market-access data; the data backbone for the agency’s access work.
• AccessGenius in Veeva and IQVIA OCE: Formulary and claims signal embedded directly into reps’ CRM, not a standalone dashboard.
• Navigator365 omnichannel HCP/DOL platform: Provider-targeting and digital amplification layer; PatientLens HITRUST i1 certification (Mar 2025).
• Launch breadth: 450+ drug launches supported; 57% of all FDA approvals in 2023 and 36% of novel approvals in 2024.

RFP Questions

• Which legacy agency (PRECISIONadvisors, PRECISIONxtract, others) leads each workstream, and who is the named senior operator?
• Which AET members will sit on our ad boards or primary-research panels?
• What Payer Master data sources, refresh cadence, geography, and use-rights are included in the scope?
• How does AccessGenius integrate with our current Veeva or IQVIA OCE deployment, and what licensing terms apply?
• Which Navigator365 outputs are deliverable to our account teams vs. internal to Precision AQ?
• How will pricing, evidence, payer engagement, and HCP activation be reconciled into one launch plan?
• How does the engagement coordinate with sibling PMG capabilities (Precision for Medicine CRO, others) when relevant?

Recent Activity

• 2026-02 - Yahya Anvar joined as SVP Data Strategy & AI; Emma Hawe joined as SVP Evidence Synthesis.
• 2025-12 - Phluence investment to advance agentic patient solutions.
• 2025-03 - PatientLens HITRUST i1 certification.
• 2025-01 - Navigator365 Matrix launched (DOL identification platform using Digital Amplification Index).
• 2025-04 - Dan Cummings joined as first-ever Chief Commercial Officer.
• 2024-10 - PMG appointed Margaret Keegan CEO.
• 2024-05 - Rebranded from Precision Value & Health to Precision AQ, unifying nine sub-brands.